Letter: new thresholds need to be defined when using point of care assays to monitor infliximab trough levels in IBD patients. [electronic resource]
Producer: 20190729Description: 1571-1573 p. digitalISSN:- 1365-2036
No physical items for this record
Publication Type: Letter; Comment
There are no comments on this title.
Log in to your account to post a comment.